No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NNVC240719C2500
- 0.02
- -0.03-60.00%
15min DelayClose Jul 18 15:58 ET
0.05High0.02Low
0.05Open0.05Pre Close103 Volume804 Open Interest2.50Strike Price215.00Turnover395.60%IV28.57%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.1183Delta0.5312Gamma98.00Leverage Ratio-0.0430Theta0.0000Rho11.60Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
News
Express News | NanoViricides Shares Are Trading Higher After the Company Announced It Discussed Its Development Program for NV-387
NanoViricides Discusses Lead Program and Next Steps | NYSE-A:NNVC
NanoViricides Is Well Positioned With Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides Hails Broad Potential of Lead Antiviral Drug as It Prepares to Begin First Phase II Trial | NYSE-A:NNVC
NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model | NYSE-A:NNVC
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broa
Comments
Follow Our Official Telegram Channel tynkrlab
$Dow Jones Industrial Average(.DJI.US$ rose by 0.59% to a new record high, closing at 41,211.12. In contrast, the $S&P 500 Index(.SPX.US$ fell by 1.39%, and the $Nasdaq Composite Index(.IXIC.US$ dropped by 2.76%. Tech stocks faced significant pressure, contributing to the mixed market performance.
Key Drivers
1. Strong Performers: $UnitedHealth(UNH.US$, $Johnson & Johnson(JNJ.US$, and $Cisco(CSCO.US$ l...
$Dow Jones Industrial Average(.DJI.US$ rose by 0.59% to a new record high, closing at 41,211.12. In contrast, the $S&P 500 Index(.SPX.US$ fell by 1.39%, and the $Nasdaq Composite Index(.IXIC.US$ dropped by 2.76%. Tech stocks faced significant pressure, contributing to the mixed market performance.
Key Drivers
1. Strong Performers: $UnitedHealth(UNH.US$, $Johnson & Johnson(JNJ.US$, and $Cisco(CSCO.US$ l...
4
$Nanoviricides(NNVC.US$
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
NanoViricides discusses its development of NV-387, a drug targeting multiple respiratory viruses including COVID, RSV, Influenza, and Bird Flu.
NV-387 has shown superior activity in animal models compared to approved drugs and has completed Phase I trials with no adverse events.
The company is planning Phase II tri...
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
NanoViricides discusses its development of NV-387, a drug targeting multiple respiratory viruses including COVID, RSV, Influenza, and Bird Flu.
NV-387 has shown superior activity in animal models compared to approved drugs and has completed Phase I trials with no adverse events.
The company is planning Phase II tri...
$Nanoviricides(NNVC.US$
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides, a leader in antiviral nanomedicines, presents the progress of its drug candidate NV-387, which has completed Phase I clinical trials with no adverse events reported. NV-387 has demonstrated significant efficacy against various viruses, including RSV, Influenza, ...
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides, a leader in antiviral nanomedicines, presents the progress of its drug candidate NV-387, which has completed Phase I clinical trials with no adverse events reported. NV-387 has demonstrated significant efficacy against various viruses, including RSV, Influenza, ...
2
$Nanoviricides(NNVC.US$ A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1
2
Read more